PHP134 - Reimbursement Decision-Making in Ukraine: Current and Future Directions

Abstract

Health technology assessment (HTA) introduction and development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016-2017. The study aimed to outline and analyze the launch of drug reimbursement programs in 2017 in line with the international requirements and future directions in Ukraine. . Literature review was conducted examining legislation database and scientific publications on the study issues in Ukraine. The state reimbursement program “Affordable Medicines” was launched in April 2017 for cardiovascular diseases, type 2 diabetes and asthma. According to Resolutions of the Cabinet of Ministers of Ukraine No.862 “On state regulation of prices on medicines” dated 09.11.2016 and No.863 “On implementation of reimbursement” dated 09.11.2016 was started implementation of the new state price regulation on the drugs. According to the bylaws such medicines have to be registered and included on the NLEM. The state budget funding was approved in the amount of 24,6 mln USD for this reimbursement program in 2017 and 35,1 mln USD for 2018 respectively. There is international reference pricing. Reference prices are calculated based on the prices in 5 countries: Poland, Latvia, Slovakia, Hungary and Czech Republic as a median reference prices for these medicines with terms DDD. The participation is voluntary both by the pharmaceutical companies and pharmacies. The reimbursement decisions are made by the MoH. Pharmaceutical company have to provide appropriate application form. The reimbursement list includes partially and fully reimbursed drugs (23 INN), approved by the Resolutions of the Cabinet of Ministers of Ukraine No. 1080 dated 27.12.2017. The quantity of consumed drugs by DDD increased by 85% in 2017. The program demonstrated the decrease in the average weighted price of drugs. The government is going to expand the list of diseases and chronic conditions by including new drugs in 2018.